Actionable news
All posts from Actionable news
Actionable news in HZNP: Horizon Pharma, Inc.,

Mizuho Top Analyst Weighs in on Horizon Pharma PLC (HZNP) After Strong 2Q:16 Revenue Beat

Horizon Pharma PLC (NASDAQ:HZNP) just roared through its second-quarter earnings results. For the quarter, the drug maker came in with $257.4 million in revenue and $0.62 in non-GAAP earnings per share (EPS), compared to consensus estimates of $235 million and $0.50 in EPS. HZNP reiterates revenue guidance for the fiscal year of 2016 in the range of $1.025 to $1.050 billion, but reduces its earnings guidance from the prior range of $505 million to $520 million down to $495 million to $510 million. This cut in earnings guidance can be attributed to the $10 million EBITDA impact following the acquisition of global rights to Actimmune, an interferon gamma-1b pipeline drug...